(Q34241289)

31 July 2017

1 reference

title

The psychobiology of anxiolytic drug. Part 2: Pharmacological treatments of anxiety (English)

1 reference

31 July 2017

1 reference

Argyropoulos SV

1

1 reference

PubMed ID

11337026

31 July 2017

Sandford JJ

series ordinal

2

1 reference

PubMed ID

11337026

31 July 2017

Nutt DJ

series ordinal

3

1 reference

31 July 2017

1 December 2000

1 reference

Pharmacology & Therapeutics

31 July 2017

1 reference

31 July 2017

88

1 reference

31 July 2017

213-227

1 reference

31 July 2017

3

1 reference

A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

A double-blind, randomized, placebo-controlled, multi-center study of brofaromine in the treatment of post-traumatic stress disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Calcium channel blockers for anxiety disorders?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

1 reference

7 January 2021

Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

A Comparison of Fluvoxamine, Cognitive Therapy, and Placebo in the Treatment of Panic Disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Study and course of the psychological profile in 77 patients expressing panic disorder with agoraphobia after cognitive behaviour therapy with or without buspirone

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Brain specific benzodiazepine receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

New concepts in benzodiazepine therapy: rebound anxiety and new indications for the more potent benzodiazepines

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

A comparison of cognitive therapy, applied relaxation and imipramine in the treatment of panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Discontinuation of clonazepam in the treatment of social phobia.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Predicting response to amitriptyline in posttraumatic stress disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Treatment of social phobia with clonazepam and placebo.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Assessment of the Efficacy of Buspirone in Patients Affected by Generalized Anxiety Disorder, Shifting to Buspirone From Prior Treatment with Lorazepam

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Recent clinical trials of hydroxyzine in generalized anxiety disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Inositol treatment of obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Treatment of social phobia with clonidine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

The SSRI discontinuation syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

The effect of beta adrenergic blocking drugs on speakers' performance and memory.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Beta-blockers in anxiety disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Imipramine and chlordiazepoxide in depressive and anxiety disorders. II. Efficacy in anxious outpatients.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Inositol treatment of post-traumatic stress disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Serotonergic (5-HT2) mediation of anxiety-therapeutic effects of serazepine in generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Pharmacotherapy of post-traumatic stress disorder with a novel psychotropic

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Sertraline for social phobia: a double-blind, placebo-controlled crossover study

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Low dose lithium carbonate in the treatment of post traumatic stress disorder: brief communication.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Psychiatric reaction patterns to imipramine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Sertraline efficacy in depressed combat veterans with posttraumatic stress disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Distinct mechanism for antidepressant activity by blockade of central substance P receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Controlled trials of inositol in psychiatry

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Phenelzine vs atenolol in social phobia. A placebo-controlled comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Preliminary study of carbamazepine in post-traumatic stress disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Randomised placebo-controlled trial of moclobemide, cognitive-behavioural therapy and their combination in panic disorder with agoraphobia.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Antidepressants in panic disorder and agoraphobia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Recent developments in the psychopharmacology of anxiety disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Clinical and medication outcome after short-term alprazolam and behavioral group treatment in panic disorder. 2.5 year naturalistic follow-up study.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Moclobemide in social phobia: a controlled dose-response trial

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Substance-P antagonists: a new treatment for depression?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Diazepam alters brain 5-HT function in man: implications for the acute and chronic effects of benzodiazepines.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Loss of consciousness and post-traumatic stress disorder. A clue to aetiology and treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Controlled comparison of buspirone and clomipramine in obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Placebo response in anxiety disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

The pharmacotherapy of social phobia.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

A controlled trial of desipramine in 18 men with posttraumatic stress disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Gepirone and diazepam in generalized anxiety disorder: a placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

A meta-analysis of the effects of venlafaxine on anxiety associated with depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Treatment of Anxiety States by Antidepressant Drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Placebo-controlled trial of moclobemide in social phobia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Long-term Therapeutic Use of Benzodiazepines

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Maintenance drug treatment for panic disorder. II. Short- and long-term outcome after drug taper

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Buspirone: an anxiolytic without sedative effect.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

A controlled trial of phenelzine in posttraumatic stress disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Medication treatments for panic disorder and social phobia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Moclobemide for anxiety disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Pharmacotherapy for post-traumatic stress disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Behavioral and physiologic effects of short-term and long-term administration of clonidine in panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Clomipramine versus phenelzine in obsessive-compulsive disorder. A controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Pharmacotherapy of Social Phobia

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Behaviour therapy and benzodiazepines: allies or antagonists?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Effects of concurrent diazepam treatment on the outcome of exposure therapy in agoraphobia.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

Treatment of phobias. I. Comparison of imipramine hydrochloride and placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

A comparison of alprazolam and behavior therapy in treatment of panic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2800%2900083-8

7 January 2021

10.1016/S0163-7258(00)00083-8

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

11337026